FDA Orange Book · active-ingredient family
Liraglutide
Liraglutide: 2 brands, 11 generics; first approved Jan 25, 2010; generic available.
Generic available1 exclusivity period
Generic status & protection
Generic available: 11 ANDA applications approved.
Earliest patent expiry Latest exclusivity ends
Brands (NDA)
2
Generics (ANDA)
11
Listed patents
4
Next patent expiry
Aug 13, 2025
1 yr 2 mo ago
Brand (NDA) products
Originator applications
- NOVONDA 2063212014
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP2 - NOVO NORDISK INCNDA 0223412010
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1
Generic (ANDA) products (11)
Abbreviated applications
- LIRAGLUTIDESANDOZANDA 2129722026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDEMYLAN INSTITUTIONALANDA 2131552026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDEFRESENIUS KABI USAANDA 2125522026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDEBIOCON PHARMAANDA 2152452026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDEBIOCON PHARMAANDA 2170632026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP2 - LIRAGLUTIDEORBICULARANDA 2172342026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP2 - LIRAGLUTIDEORBICULARANDA 2175902026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDETEVA PHARMSANDA 2145682025
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP2 - LIRAGLUTIDELUPINANDA 2154212025
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDENANJING KING FRIENDANDA 2181152025
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1 - LIRAGLUTIDEHIKMAANDA 2155032024
Approved strengths under this FDA application. Strength Dosage form Route Status TE 18MG/3ML (6MG/ML) SOLUTION SUBCUTANEOUS Rx AP1
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Marketing exclusivity
Hatch-Waxman
- PCPatent-challenge (180-day generic) exclusivity
8 mo ago
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 8114833 | 1 yr 2 mo ago | Product | |
| 8114833*PED | 8 mo ago | ||
| 9968659 | in 10 yr 5 mo | U-2438 | |
| 9968659*PED | in 10 yr 11 mo |
Approval history
FDA approval span
First approval
17 yr ago
Most recent approval
4 mo ago
Approvals span 2010–2026 across 13 FDA applications.
Brand (NDA) 215%
Generic (ANDA) 1185%
Liraglutide: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Go beyond the database.
Try Assyro Intelligence for your regulatory research. Ready to discuss your team’s workflow? Book a demo.